JC

Joseph Charalel

Life sciences investor at Pivotal bioVenture Partners

Stanford, California

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Vice President

    2024

    • Lead diligence / source new investment deals • Support portfolio companies at the board level • Manage positions in public biotech portfolio companies

  • Senior Associate

    2022 - 2023

2023

  • Board Observer

    2023

  • Board Observer

    2022

  • Board Observer

    2022

  • PhD Candidate in Genetics

    2013

    • Perform research in the laboratory of Dr. Christina Curtis on the genetic and epigenetic basis of drug resistance in HER2+ breast cancers via multi-omic profiling. Focus on using genome-wide sequencing assays and machine learning to understand drug response using in vitro model systems and patient data. (2015-Present) • Researcher in the laboratory of Dr. Atul Butte (now at UCSF). Worked on in silico characterization of cancer cell lines as tumor models using publicly available omics data. (2014-2015)

  • Guest Lecturer

    2023

    Guest lecturer on valuation methodology - INDE 209: Analysis of Public Companies in the Life Sciences

2023 - 2024

  • Board Observer

    2023 - 2024

2018 - 2021

  • Manager

    2018 - 2021

    Focused on healthcare and investment due diligence

  • General Partner

    2017 - 2018

    • Equity partner and manager in small-cap biotech fund led by Stanford trainees

2017 - 2018

  • Intern

    2017 - 2018

    • Performed due diligence to identify potential new investment opportunities and develop comprehensive thesis for a particular therapeutic area • Contributed to company analysis efforts which led to investment decisions • Led key opinion leader calls, analyzed primary research literature, analyst reports to develop comprehensive commercial and scientific view of the key opportunities in the space • Synthesized and presented findings to Longitude leadership